FDA cleared the AesyBite Active from Aesyra SA on Oct 30, 2026 under K260360, a traditional 510(k). The device falls under product code HCC, Device, Biofeedback, regulated at 21 CFR 882.5050 as a Class 2 device. The review panel was Neurology.
FDA logged the submission as received on Feb 4, 2026. The decision came 268 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.
This is the only decision on file for Aesyra SA in the last 12 months of the tracker.